We use cookies to ensure that we give you the best experience on our website Learn more

My documents

Jun 18, 2019

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

09 - EFFICACY OF STEROID THERAPY FOR END-OF-LIFE TREATMENT IN PATIENTS WITH ADVANCED LUNG CANCER TRANSFERRED TO PALLIATIVE CARE UNIT

;

Abstract

Abstract

thumbnail

Keywords

Abstract

Background: Corticosteroids (CS) have many indications for a variety of use in palliative care, and many patients with advanced lung cancer (ALC) are administered systemic CS from the time of diagnosis to end-of life. But using CS must be careful of the risks of higher side effects. Objectives: This retrospective study, clinical investigations of patients with ALC who underwent CS therapy after transfer were conducted, and the effects and side effects were evaluated. Methods: In 75 ALC patients who were directly transferred for the purpose of end-of-life care and died in our palliative care unit between January 2014 and December 2018. Clinical background, a beginning period of dosage, the reason for use, the type of medicine, the dosage, were examined. Also, for the administration cases were assessed for their effectiveness and side effects. Results: The median age was 75 (range, 54-93) years, and 22 patients (29.3%) were female. CS were administered for improvement of symptoms, used 18 patients before hospitalization, 12 patients immediately after hospitalization administered or increased, and 12 patients at intervals, but 33 patients did not use. The purpose of administration was mainly used for dyspnea, general fatigue, anorexia, and/or pain. In patients treated with CS, 13 patients (31.0%) had even temporarily improved their symptoms up until death, and type of CS was no related, but after hospitalization, early dosing tended to be more effective. Conclusion: Although our cohort was small, ALC patients can help determine the success of symptomatic relief, if better managed using steroid therapy.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.